Lycia Therapeutics

9 articles about Lycia Therapeutics

• Nona Biosciences Announces Collaboration Agreement with Lycia Therapeutics

  12/4/2023

  Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, announced it has entered into a collaboration agreement with Lycia Therapeutics, a leader in extracellular protein degradation.

• Lycia Therapeutics to Present at Jefferies 2023 Healthcare Conference

  6/5/2023

  Lycia Therapeutics, Inc., a leader in extracellular protein degradation, announced that Aetna Wun Trombley, Ph.D., President and Chief Executive Officer of Lycia, will present a corporate overview at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 2:00 pm ET in New York.

• Lycia Therapeutics Founder Dr. Carolyn Bertozzi Awarded 2022 Nobel Prize in Chemistry

  10/5/2022

  Lycia Therapeutics, Inc. announced that founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in Chemistry.

• Lycia Therapeutics Strengthens Leadership Team with Appointment of Steve Staben, Ph.D. as Chief Scientific Officer

  2/28/2022

  Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the recent appointment of Steve Staben, Ph.D., as Chief Scientific Officer.

• 

  Avilar Debuts to Pioneer Extracellular Protein Degradation

  11/18/2021

  Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.
• 

  Money on the Move: September 8 – 14

  9/15/2021

  Ramping up after the Labor Day holiday, funds are flowing fast and free into these life science companies.

• Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures

  9/9/2021

  Lycia Therapeutics, Inc. today announced the completion of an oversubscribed $70 million Series B financing.

• 

  Lilly and Lycia Ink Collaboration and Licensing Deal Worth Up to $1.6 Billion

  8/26/2021

  Lycia will be receiving a $35 million upfront payment from Lilly and is eligible for over $1.6 billion in potential milestone payments.

• Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders

  8/25/2021

  Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology.